Management of iron overload before, during, and after hematopoietic stem cell transplantation for thalassemia major

Annals of the New York Academy of Sciences

Volumn 1368, Issue 1, 2016, Pages 115-121

  Angelucci, Emanuele ^a   Pilo, Federica ^a  

^a Ospedale Oncologico A Businco   (Italy)

Author keywords

Hematopoietic stem cell transplantation; Iron overload; LPI; NTBI; Thalassemia

Indexed keywords

DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; FERRITIN; IRON; REACTIVE OXYGEN METABOLITE; BENZOIC ACID DERIVATIVE; IRON CHELATING AGENT; TRIAZOLE DERIVATIVE;

ARTICLE; BONE MARROW DERIVED MESENCHYMAL STEM CELL; BONE MARROW DERIVED MONONUCLEAR CELL; CELL DIFFERENTIATION; CHELATION THERAPY; DNA DAMAGE; ERYTHROCYTE TRANSFUSION; ERYTHROPOIESIS; FERRITIN BLOOD LEVEL; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IRON BLOOD LEVEL; IRON CHELATION; IRON DEPLETION; IRON METABOLISM; IRON OVERLOAD; LIPID PEROXIDATION; MICROENVIRONMENT; NONHUMAN; OXIDATIVE STRESS; PHLEBOTOMY; PROTEIN MODIFICATION; THALASSEMIA MAJOR; TRANSPLANTATION CONDITIONING; ADVERSE EFFECTS; ANIMAL; BETA-THALASSEMIA; BLOOD; DISEASE MANAGEMENT; TRENDS;

ANIMALS; BENZOATES; BETA-THALASSEMIA; DISEASE MANAGEMENT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; TRIAZOLES;

EID: 84962204190     PISSN: 00778923     EISSN: 17496632     Source Type: Journal    
DOI: 10.1111/nyas.13027     Document Type: Article

References (40)

1. Rachmilewitz, E.A. & P.J. Giardina . 2011. How I treat thalassemia. Blood 118: 3479-3488.
2. Bacon, B.R., R. O'Neill & R.S. Britton . 1993. Hepatic mitochondrial energy production in rats with chronic iron overload. Gastroenterology 105: 1134-1140.
3. Angelucci, E. 2010. Hematopoietic stem cell transplantation in thalassemia. Hematology Am. Soc. Hematol. Educ. Program 2010: 456-462.
4. Glickstein, H., E.R. Ben, M. Shvartsman & Z.I. Cabantchik . 2005. Intracellular labile iron pools as direct targets of iron chelators: a fluorescence study of chelator action in living cells. Blood 106: 3242-3250.
5. Porter, J.B. & M. Garbowski . 2014. The pathophysiology of transfusional iron overload. Hematol. Oncol. Clin. North Am. 28: 683-701.
6. Cabantchik, Z.I., W. Breuer, G. Zanninelli & P. Cianciulli . 2005. LPI-labile plasma iron in iron overload. Best Pract. Res. Clin. Haematol. 18: 277-287.
7. Jomova, K. & M. Valko . 2011. Advances in metal-induced oxidative stress and human disease. Toxicology 283: 65-87.
8. Zhang, Y., W. Zhai, M. Zhao, et al. 2015. Effects of iron overload on the bone marrow microenvironment in mice. PLoS One 10: e0120219.
9. Prus, E. & E. Fibach . 2011. Uptake of non-transferrin iron by erythroid cells. Anemia 2011: 945289.
10. Hartmann, J., F. Braulke, U. Sinzig, et al. 2013. Iron overload impairs proliferation of erythroid progenitors cells (BFU-E) from patients with myelodysplastic syndromes. Leuk. Res. 37: 327-332.
11. Taoka, K., K. Kumano, F. Nakamura, et al. 2012. The effect of iron overload and chelation on erythroid differentiation. Int. J. Hematol. 95: 149-159.
12. Angelucci, E., V. Santini, A.A. Di Tucci, et al. 2014. Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial). Eur. J. Haematol. 92: 527-536.
13. Chai, X., D. Li, X. Cao, et al. 2015. ROS-mediated iron overload injures the hematopoiesis of bone marrow by damaging hematopoietic stem/progenitor cells in mice. Sci. Rep. 5: 10181.
14. Lucarelli, G., M. Galimberti, P. Polchi, et al. 1993. Marrow transplantation in patients with thalassemia responsive to iron chelation therapy. N. Engl. J. Med. 329: 840-844.
15. Lucarelli, G., M. Galimberti, P. Polchi, et al. 1990. Bone marrow transplantation in patients with thalassemia. N. Engl. J. Med. 322: 417-421.
16. Lucarelli, G., R.A. Clift, M. Galimberti, et al. 1996. Marrow transplantation for patients with thalassemia: results in class 3 patients. Blood 87: 2082-2088.
17. Lucarelli, G., M. Galimberti, P. Polchi, et al. 1990. Bone marrow transplantation in patients with thalassemia. N. Engl. J. Med. 322: 417-421.
18. Angelucci, E., S. Matthes-Martin, D. Baronciani, et al. 2014. Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel. Haematologica 99: 811-820.
19. Dürken, M., P. Nielsen, S. Knobel, et al. 1997. Nontransferrin-bound iron in serum of patients receiving bone marrow transplants. Free Radic. Biol. Med. 22: 1159-1163.
20. Muretto, P., S. Del Fiasco, E. Angelucci, et al. 1994. Bone marrow transplantation in thalassemia: modifications of hepatic iron overload and associated lesions after long-term engrafting. Liver 14: 14-24.
21. Platzbecker, U., M. Bornhäuser, U. Germing, et al. 2008. Red blood cell transfusion dependence and outcome after allogeneic peripheral blood stem cell transplantation in patients with de novo myelodysplastic syndrome (MDS). Biol. Blood Marrow Transplant. 14: 1217-1225.
22. Alessandrino, E.P., M.G. Della Porta, A. Bacigalupo, et al. 2010. Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a GITMO study. Haematologica 95: 476-484.
23. Pullarkat, V., S. Blanchard, B. Tegtmeier, et al. 2008. Iron overload adversely affects outcome of allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 42: 799-805.
24. Kataoka, K., Y. Nannya, A. Hangaishi, et al. 2009. Influence of pretransplantation serum ferritin on nonrelapse mortality after myeloablative and nonmyeloablative allogeneic hematopoietic stem cell transplantation. Biol. Blood Marrow Transplant. 15: 195-204.
25. Armand, P., H.T. Kim, C.S. Cutler, et al. 2007. Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood 109: 4586-4588.
26. Gaziev, D., P. Polchi, M. Galimberti, et al. 1997. Graft-versus-host disease after bone marrow transplantation for thalassemia: an analysis of incidence and risk factors. Transplantation 63: 854-860.
27. Gaziev, D., C. Giardini, E. Angelucci, et al. 1995. Intravenous chelation therapy during transplantation for thalassemia. Haematologica 80: 300-304.
28. Lee, S.E., S.A. Yahng, B.S. Cho, et al. 2013. Improvement in hematopoiesis after iron chelation therapy with deferasirox in patients with aplastic anemia. Acta Haematol. 129: 72-77.
29. Vallejo, C., M. Batlle, L. Vazquez, et al. 2014. Phase IV open-label study of the efficacy and safety of deferasirox after allogeneic stem cell transplantation. Haematologica 99: 1632-1637.
30. Sivgin, S., B. Eser, S. Bahcebasi, et al. 2012. Efficacy and safety of oral deferasirox treatment in the posttransplant period for patients who have undergone allogeneic hematopoietic stem cell transplantation (alloHSCT). Ann. Hematol. 91: 743-749.
31. Sivgin, S., S. Baldane, G. Akyol, et al. 2013. The oral iron chelator deferasirox might improve survival in allogeneic hematopoietic cell transplant (alloHSCT) recipients with transfusional iron overload. Transfus. Apher. Sci. 49: 295-301.
32. Lucarelli, G., E. Angelucci, C. Giardini, et al. 1993. Fate of iron stores in thalassaemia after bone-marrow transplantation. Lancet 342: 1388-1391.
33. Angelucci, E., P. Muretto, A. Nicolucci, et al. 2002. Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation. Blood 100: 17-21.
34. Angelucci, E., P. Muretto, G. Lucarelli, et al. 1998. Treatment of iron overload in the "ex-thalassemic." Report from the phlebotomy program. Ann. N. Y. Acad. Sci. 850: 288-293.
35. Mariotti, E., E. Angelucci, A. Agostini, et al. 1998. Evaluation of cardiac status in iron-loaded thalassaemia patients following bone marrow transplantation: improvement in cardiac function during reduction in body iron burden. Br. J. Haematol. 103: 916-921.
36. Angelucci, E., P. Muretto, G. Lucarelli, et al., and Italian Cooperative Group for Phlebotomy Treatment of Transplanted Thalassemia Patients. 1997. Phlebotomy to reduce iron overload in patients cured of thalassemia by bone marrow transplantation. Blood 90: 994-998.
37. Li, C.K., D.H. Lai, M.M. Shing, et al. 2000. Early iron reduction programme for thalassaemia patients after bone marrow transplantation. Bone Marrow Transplant. 25: 653-656.
38. Giardini, C., M. Galimberti, G. Lucarelli, et al. 1995. Desferrioxamine therapy accelerates clearance of iron deposits after bone marrow transplantation for thalassaemia. Br. J. Haematol. 89: 868-873.
39. Pontikoglou, C. & H.A. Papadaki . 2010. Idiosyncratic drug-induced agranulocytosis: the paradigm of deferiprone. Hemoglobin 34: 291-304.
40. Muretto, P., E. Angelucci & G. Lucarelli . 2002. Reversibility of cirrhosis in patients cured of thalassemia by bone marrow transplantation. Ann. Intern. Med. 136: 667-672.